Page last updated: 2024-10-25

cilostazol and Carcinoma, Epidermoid

cilostazol has been researched along with Carcinoma, Epidermoid in 1 studies

Research Excerpts

ExcerptRelevanceReference
"We previously reported that human squamous cell carcinoma (SCC) cell lines refractory to cis-diaminedichloro-platinum II (cisplatin [CDDP]) had significant upregulation of the phosphodiesterase 3B gene (PDE3B), suggesting that inhibiting PDE3B suppresses CDDP resistance."1.39Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells. ( Baba, T; Iyoda, M; Kasamatsu, A; Ogawara, K; Saito, Y; Sakamoto, Y; Sakuma, K; Shiiba, M; Tanzawa, H; Usukura, K; Uzawa, K, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Uzawa, K1
Kasamatsu, A1
Baba, T1
Usukura, K1
Saito, Y1
Sakuma, K1
Iyoda, M1
Sakamoto, Y1
Ogawara, K1
Shiiba, M1
Tanzawa, H1

Other Studies

1 other study available for cilostazol and Carcinoma, Epidermoid

ArticleYear
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
    Cancer medicine, 2013, Volume: 2, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Carcinoma, Squamous

2013